All of the GT2a‐infected patients without treatment‐emergent substitutions detected in NS3 and NS5A received 12 weeks of treatment, indicating that 16 weeks of treatment may be required to fully suppress replication of wild‐type virus in HCV GT2a infection. The gene discussed is KRAS; the disease is infection.